Amazon to Test Drones to Deliver Prescriptions to Your Door
THURSDAY, Oct. 19, 2023 (HealthDay News) — Soon, you may be able to step out on your front porch and wait for your prescription medication to drop from the sky. On Wednesday, Amazon Pharmacy announced that it is starting to test speedy prescription d…
Learn MoreBetter Health Care Access Is Helping People With Down Syndrome Live Longer
THURSDAY, Oct. 19, 2023 (HealthDay News) — Americans with Down syndrome have a critical lifeline in Medicaid insurance, new research confirms.But the publicly funded insurance program will have to respond to rising numbers of older adults with Down s…
Learn MoreExtra Antibiotic With Hip, Knee Replacement Won’t Prevent Infections: Study
THURSDAY, Oct. 19, 2023 (HealthDay News) — Millions of people undergo joint replacement surgery every year. To prevent infection, doctors often give them a second antibiotic — but new research suggests this can backfire.Adding a second antibiotic at…
Learn MoreTelemedicine Could Improve Treatment for Opioid Use Disorder
THURSDAY, Oct. 19, 2023 (HealthDay News) — Telehealth may be a powerful way to get people with opioid use disorder to take — and stay on — medication to treat their addiction.Researchers report that those who started buprenorphine treatment via tel…
Learn MoreLesbian & Gay Teens Have Twice the Odds for Binge-Eating Disorders
THURSDAY, Oct. 19, 2023 (HealthDay News) — Stigma can take a toll on lesbian, gay and bisexual teens, leading to high rates of binge-eating disorders, researchers say.Compared to their non-LGBTQ peers, lesbian, gay and bisexual teens are more than t…
Learn MorePositive Link Identified Between SARS-CoV-2 and Guillain-Barré
WEDNESDAY, Oct. 18, 2023 (HealthDay News) — There is a positive association for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Guillain-Barré syndrome (GBS), and a negative association for COVID-19 vaccination and GBS, acc…
Learn MoreEnzalutamide + Leuprolide Top for Mets-Free Survival in Prostate Cancer
WEDNESDAY, Oct. 18, 2023 (HealthDay News) — For patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide is best for metastasis-free survival, according to a study published in the Oct. 19 issue of the New Eng…
Learn More